Vicore Pharma Holding (NASDAQ:VCRE) Sees Large Drop in Short Interest

Vicore Pharma Holding (NASDAQ:VCRE) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 4,238 shares, a decrease of 57.0% from the September 15th total of 9,857 shares. Based on an average daily trading volume, of 39,075 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VCRE. Weiss Ratings began coverage on Vicore Pharma in a research report on Thursday, October 8th. They issued a “sell (e-)” rating for the company. Jefferies Financial Group initiated coverage on Vicore Pharma in a research report on Friday, October 9th. They set a “buy” rating and a $25.00 target price on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.00.

Vicore Pharma Trading Down 1.1%

Shares of NASDAQ:VCRE traded down $0.10 during mid-day trading on Thursday, hitting $8.98. The company had a trading volume of 26,642 shares, compared to its average volume of 27,869. Vicore Pharma has a one year low of $7.88 and a one year high of $17.80.

About Vicore Pharma

Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.

Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor.